Biotech Startups Rely on Different Types of Funding
Private foundations are also filling this void. For example, a five-year $12.5 million grant from the Bill and Melinda Gates Foundation to Amyris Biotechnologies (Emeryville, California) is funding development of biotechnology methods to produce the anti-malaria drug artemisinin. Artemisinin is currently in short supply and improved production methods are needed.
Since 2004, UCTTO has deployed $11.5 million to fund 139 projects according to Rick Silva. Eight of these have become startup firms with equity. Another 44 have been licensed or optioned by investors.
UCTTO projects have received $53 million from other sources for technology development and $173 million in venture capital investment. Perhaps the biggest success story is Taligen Therapeutics (Aurora, Colorado). Started in 2004 with UCTTO seed money, there were four rounds of venture capital funding totaling over $70 million. In 2010 the first patient was treated with Taligen's drug for Marchiafava-Micheli syndrome, a rare life-threatening blood disease. In 2011 Alexion Pharmaceuticals acquired Taligen for $111 million.
State and Local Support
MOSIRA is the Missouri Science and Innovation Reinvestment Act. CEO Derek Rapp of startup Divergence, Inc. notes, "The passage of MOSIRA is a big step in promoting formation and growth of startups." It enables the state "to provide a predictable, stable source of funding for building the entrepreneurial infrastructure necessary to support the growth of science and innovation companies in Missouri," says Donn Rubin, executive director of The Coalition for Plant and Life Sciences.
This infrastructure includes incubator space, space for post-incubator companies, multi-tenant space, pilot or full-scale manufacturing space, and research park development for clustering young and mature companies. Rubin notes that MOSIRA enables Missouri to provide the matching funds necessary to attract new jobs and investment to the state.
BioSTL, formed last September in the St. Louis area, is a new regional organization aimed at transforming local innovations into new biotechnology companies. Washington University in St. Louis, BJC HealthCare, and the St. Louis Life Sciences Project have provided $30 million in funding for the next five years.
Venture capitalists are still funding some biotechnology startups. Mirina Corp. recently received funding from Accelerator, a Seattle-based biotechnology investment company. Mirina is developing biotechnology that could be useful in treating cancer. And Google Ventures funded a Lebanon, New Hampshire biotechnology startup called Adimab. It uses technology developed by the Massachusetts Institute of Technology and Dartmouth College to develop genetically engineered versions of specialized human body proteins.
Divergence, Inc. also relied on venture capitalists. It began operations in 1999 in St. Louis to develop products to control and prevent plant root parasites called nematodes. Monsanto acquired the company in early 2011 for $76 million.
SafeSource Direct Plans Lafayette Parish and St. Martin Parish, Louisiana, PPE Manufacturing Centers
35th Annual Corporate Survey: Effects of Global Pandemic Reflected in Executives’ Site and Facility Plans
What’s Driving Record Industrial Real Estate Demand
Mitigate the Risks of Supply Chain Disruption
Life Sciences Fueling Construction Demand
Challenges of Moving Manufacturing Out of China
35th Annual Survey of Corporate Executives Commentary: Change in Site Selection Priorities and Plans Over the Short and Long Term